| 王展,王文瑾,丁晓艳,卢鹏,竺丽梅,刘巧,陆伟.利福平耐药结核病患者接触者预防性治疗研究进展[J].Chinese journal of Epidemiology,2023,44(3):470-476 |
| 利福平耐药结核病患者接触者预防性治疗研究进展 |
| Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients |
| Received:July 29, 2022 |
| DOI：10.3760/cma.j.cn112338-20220729-00673 |
| KeyWord: 结核病 利福平耐药 耐多药 潜伏感染 预防性治疗 |
| English Key Word: Tuberculosis Rifampicin-resistance Multi-drug resistance Latent infection Prophylactic therapy |
| FundProject:国家自然科学基金（82003516）；江苏省卫生健康委员会科研重点项目（ZD2021052，ZDA2020022）；江苏省卫生健康委员会科研面上项目（M2020020） |
| Author Name | Affiliation | E-mail | | Wang Zhan | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China
Department of Epidemiology for School of Public Health, Nanjing Medical University, Nanjing 211166, China | | | Wang Wenjin | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China
Department of Epidemiology for School of Public Health, Nanjing Medical University, Nanjing 211166, China | | | Ding Xiaoyan | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China | | | Lu Peng | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China | | | Zhu Limei | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China | | | Liu Qiao | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China | liuqiaonjmu@163.com | | Lu Wei | Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China
Department of Epidemiology for School of Public Health, Nanjing Medical University, Nanjing 211166, China | jsjkmck@163.com |
|
| Hits: 3055 |
| Download times: 905 |
| Abstract: |
| 对结核潜伏感染者开展预防性治疗可减少感染人群发生结核病的机会，是控制结核病的一项重要措施。我国推荐对部分重点人群的结核潜伏感染者开展预防性治疗，从而减少结核病发病的风险。耐多药/利福平耐药结核病患者接触者感染耐药病原体的风险高，但是目前对于接触耐多药/利福平耐药结核病患者的感染者还没有推荐的预防性治疗方案，本文检索文献、指南、专家共识和技术规范，对目前耐多药/利福平耐药结核病患者接触者预防性治疗方案和保护效果进行综述，为结核潜伏感染防控提供参考依据。 |
| English Abstract: |
| Tuberculosis (TB) prophylactic therapy for latent infection, which can reduce the risk for the development of active TB, is an important measure in TB control. China recommends prophylactic therapy for latent tuberculosis infection (LTBI) in some key populations to reduce the risk for TB. Contacts of patients with multi-drug and rifampicin-resistant TB (MDR/RR-TB) are at high risk for the infection with drug-resistant pathogen, however, no unified prophylactic therapy regimen has been recommended for LTBI due to exposure to MDR/RR-TB patients. This paper summarizes the current MDR/RR-TB prophylactic therapy regimen and its protection effect based on the results of the retrieval of literature, guidelines, expert consensus and technical specifications to provide reference for the prevention and control of LTBI. |
|
View Fulltext
Html FullText
View/Add Comment Download reader |
| Close |
|
|
|